Customize your JAMA Network experience by selecting one or more topics from the list below.
Kojima H, Iida M, Yaguchi Y, et al. Enhancement of Cisplatin Sensitivity in Squamous Cell Carcinoma of the Head and Neck Transfected With a Survivin Antisense Gene. Arch Otolaryngol Head Neck Surg. 2006;132(6):682–685. doi:10.1001/archotol.132.6.682
To study a new method for treating squamous cell carcinoma of the head and neck using a survivin antisense gene.
An adenoviral vector encoding surviving antisense was used for in vitro and in vivo experiments. KB cells were treated with pAd.CMV[cytomegalovirus]-antisurvivin. Western blot analysis, in vitro cytotoxic assay, and in vivo experiment were performed.
In vitro and in vivo study of head and neck cancer cell line KB.
Male, 5-week-old BALB/c nude mice.
Main Outcome Measures
Expression of survivin was assessed using Western blot analysis. The effect of antisurvivin to KB cells was measured by cytotoxic assay (in vitro) and tumor volume (in vivo).
In the in vitro experiments, transduction of the survivin antisense gene caused a nearly 12-fold increase in the sensitivity of KB cells to cisplatin, as reflected by the 50% inhibitory concentration. In in vivo experiments in nude mice, tumor growth was more inhibited by the combination of cisplatin and survivin antisense gene transduction compared with either alone.
These findings suggest that survivin targeting with adenoviral antisense vectors might be used for selective therapy of squamous cell carcinomas of the head and neck.
Create a personal account or sign in to: